The new combination medication sold under the brand name Liptruzet combines ezetimibe (Zetia) and atorvastatin (Lipitor). It will be available in four doses, combining 10 milligrams of Zetia with either 10, 20, 40 or 80mg of atorvastatin. Merck is the maker of Vytorin (a combination of Zetia and simvastatin (Zocor), which is undergoing a long-term study evaluating whether it reduces heart attacks and strokes better than simvastatin alone.
What impact do new cholesterol medications make on your patients? Do they ask your advice regarding a switch if their cholesterol is not well controlled?
For more information, please see the article in Reuters.
“Image courtesy of Stuart Miles/FreeDigitalPhotos.net.”